Effect of antiretroviral drugs on the quality of semen

Journal of Medical Virology

Volumn 83, Issue 8, 2011, Pages 1391-1394

  Lambert Niclot, Sidonie ^a   Poirot, Catherine ^a   Tubiana, Roland ^a   Houssaini, Allal ^a   Soulié, Cathia ^a   Dominguez, Stéphanie ^a   Schubert, Benoit ^a   Prades, Marie ^a   Bonmarchand, Manuela ^a   Calvez, Vincent ^a   Flandre, Philippe ^a   Peytavin, Gilles ^b   Marcelin, Anne Geneviève ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Antiretrovirals drugs; Penetration score; Semen quality

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ARTICLE; CHI SQUARE DISTRIBUTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; DRUG PENETRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM; RETROSPECTIVE STUDY; SEMEN ANALYSIS; SPERMATOZOON MOTILITY; SPERMATOZOON PENETRATION;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LOCOMOTION; MALE; RETROSPECTIVE STUDIES; SEMEN; SPERMATOZOA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79959249157     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22119     Document Type: Article

References (17)

1. Bujan L, Sergerie M, Moinard N, Martinet S, Porte L, Massip P, Pasquier C, Daudin M. 2007. Decreased semen volume and spermatozoa motility in HIV-1-infected patients under antiretroviral treatment. J Androl 28: 444-452.
2. Donnelly ET, O'Connell M, McClure N, Lewis SE. 2000. Differences in nuclear DNA fragmentation and mitochondrial integrity of semen and prepared human spermatozoa. Hum Reprod 15: 1552-1561.
3. Dulioust E, Du AL, Costagliola D, Guibert J, Kunstmann JM, Heard I, Juillard JC, Salmon D, Leruez-Ville M, Mandelbrot L, Rouzioux C, Sicard D, Zorn JR, Jouannet P, De Almeida M. 2002. Semen alterations in HIV-1 infected men. Hum Reprod 17: 2112-2118.
4. Dumond J, Yeh R, Patterson A, Corbett A, Jung BH, Rezk N, Bridges A, Dempsey E, Cohen M, Kashuba A. 2006. First dose and steady-state genital tract pharmacokinetics of ten antiretroviral drugs in HIV-infected women: Implications for pre- and post- exposure prophylaxis. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO: Foundation of Retrovirology and Human Health, Alexandria, VA.
5. Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, Katlama C, Viard JP, Treluyer JM, Rouzioux C. 2004. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Aids 18: 1958-1961.
6. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. 1999. Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 43: 1817-1826.
7. May-Panloup P, Chretien MF, Savagner F, Vasseur C, Jean M, Malthiery Y, Reynier P. 2003. Increased sperm mitochondrial DNA content in male infertility. Hum Reprod 18: 550-556.
8. Nicopoullos JD, Almeida PA, Ramsay JW, Gilling-Smith C. 2004. The effect of human immunodeficiency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Hum Reprod 19: 2289-2297.
9. Pereira AS, Smeaton LM, Gerber JG, Acosta EP, Snyder S, Fiscus SA, Tidwell RR, Gulick RM, Murphy RL, Eron JJ Jr. 2002. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J Infect Dis 186: 198-204.
10. Reddy YS, Kashuba A, Gerber J, Miller V. 2003. Roundtable report: Importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res Hum Retroviruses 19: 167-176.
11. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. 2003. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 47: 238-243.
12. Taylor S, Back DJ, Drake SM, Workman J, Reynolds H, Gibbons SE, White DJ, Pillay D. 2001. Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother 48: 351-354.
13. van Leeuwen E, Ter Heine R, van der Veen F, Repping S, Beijnen JH, Prins JM. 2007. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 51: 335-337.
14. van Leeuwen E, Wit FW, Prins JM, Reiss P, van der Veen F, Repping S. 2008a. Semen quality remains stable during 96 weeks of untreated human immunodeficiency virus-1 infection. Fertil Steril 90: 636-641.
15. van Leeuwen E, Wit FW, Repping S, Eeftinck Schattenkerk JK, Reiss P, van der Veen F, Prins JM. 2008b. Effects of antiretroviral therapy on semen quality. Aids 22: 637-642.
16. van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, Sommadossi JP, Burger DM, Lange JM, Hoetelmans RM, Prins JM. 2000. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. Aids 14: 1187-1194.
17. World Health Organisation (WHO). 1992. WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction. Cambridge, UK: Cambridge.